Literature DB >> 29497909

Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer.

Milan Spasojevic1, Anthony B Mariathasan2, Mariusz Goscinski2, Ebbe B Thorgersen2, Arne M Solbakken2, Hans-Petter Gullestad3, Truls Ryder3, Kjersti Flatmark2,4,5, Stein G Larsen2.   

Abstract

BACKGROUND: Radiotherapy (RT) and subsequent abdominoperineal resection (APR) for locally advanced rectal cancer (LARC) is associated with significant perineal wound morbidity. The aim of the present study was to investigate if vertical rectus abdominis musculocutaneous (VRAM) flap repair after APR in LARC patients improves perineal wound healing compared with direct perineal wound closure (non-VRAM).
METHODS: LARC patients (n = 329) operated with APR between January 2006 and December 2015 after neoadjuvant RT of ≥ 25 Gy were identified, including 260 and 69 patients in the non-VRAM and VRAM groups, respectively. Perineal wound healing was assessed 3 months postoperatively, and risk factors for perineal wound complications and associations with short- and long-term outcome were analyzed.
RESULTS: Delayed perineal wound healing after 3 months was more frequent in the non-VRAM group (31.5%) compared with the VRAM group (10.4%) (p < 0.01). In the non-VRAM group, 26.9% of patients developed pelvic abscess, compared with 10.1% in the VRAM group (p < 0.01). Significant risk factors for perineal wound morbidity were non-VRAM (odds ratio [OR] 3.94, 95% confidence interval [CI] 1.72-9.00; p = 0.02), positive circumferential resection margin (R1; OR 3.64, 95% CI 1.91-6.93; p < 0.01), pelvic abscess (OR 3.27, 95% CI 1.90-5.63; p < 0.01), and short-course RT (OR 3.81, 95% CI 1.75-8.30; p < 0.01). Perineal wound morbidity was not associated with impaired long-term oncologic outcome.
CONCLUSIONS: VRAM flap reconstruction of the perineum is associated with an increased wound healing rate and may protect against pelvic abscess development. However, procedure-related long-term morbidity is incompletely studied and the procedure should be reserved for selected patients.

Entities:  

Mesh:

Year:  2018        PMID: 29497909     DOI: 10.1245/s10434-018-6363-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Interdisciplinary Surgical Approaches in Vaginal and Perineal Reconstruction of Advanced Rectal and Anal Female Cancer Patients.

Authors:  Raymund E Horch; Ingo Ludolph; Aijia Cai; Klaus Weber; Robert Grützmann; Andreas Arkudas
Journal:  Front Oncol       Date:  2020-05-13       Impact factor: 6.244

2.  Feasibility of a subcutaneous gluteal turnover flap without donor site scar for perineal closure after abdominoperineal resection for rectal cancer.

Authors:  R D Blok; J A W Hagemans; J W A Burger; J Rothbarth; J D W van der Bilt; O Lapid; R Hompes; P J Tanis
Journal:  Tech Coloproctol       Date:  2019-08-20       Impact factor: 3.781

3.  Dorsal approach with tailored partial sacrectomy and gluteal V-Y fasciocutaneous advancement flap for the management of recurrent pelvic sepsis; case report.

Authors:  Sebastian Sparenberg; Sarah Sharabiany; Gijsbert D Musters; Brenda M Castano Borrero; Roel Hompes; Oren Lapid; Pieter J Tanis
Journal:  BMC Surg       Date:  2021-04-15       Impact factor: 2.102

Review 4.  Ten-Year experience with vertical rectus abdominis myocutaneous flap for reconstruction of abdominoperineal resection defects.

Authors:  Gabrielle A LaBove; Gregory Rd Evans; Brian Biggerstaff; Brandon K Richland; Seung Ah Lee; Derek A Banyard; Nima Khoshab
Journal:  JPRAS Open       Date:  2020-11-30

5.  Risk factors for delayed perineal wound healing and its impact on prolonged hospital stay after abdominoperineal resection.

Authors:  Chu-Cheng Chang; Yuan-Tzu Lan; Jeng-Kai Jiang; Shih-Ching Chang; Shung-Haur Yang; Chun-Chi Lin; Hung-Hsin Lin; Huann-Sheng Wang; Wei-Shone Chen; Tzu-Chen Lin; Jen-Kou Lin
Journal:  World J Surg Oncol       Date:  2019-12-21       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.